educational presentation
1st HIV+ to HIV-, in 1995 Serodeconversion 1st HIV cure: Demetrius B & Natures-v.com Interview
First HIV Serodeconversion | 1st person to go from HIV+ to HIV- to Serodeconverted in 1995 treatment created by Bio-Medical Scientist Victer Muhammad of Life Sciences of Washington Inc. Interview w/ Natures-v.com announced @ the Million Man March 10-16-95
Understanding the Historical Record in the use of Interferon Alpha to Combat the CoronaVirus
"Understanding the Historical Record in the use of Interferon Alpha to Combat the CoronaVirus" w/ Victer Muhammad & Dr. Patrice Muhammad, Natures-v.com.
Comprehending and Arresting the Complex Mental Health Pathologies in the New Millennium Human
Comprehending and Arresting the Complex Mental Health Pathologies in the New Millennium Human w/ Victer Muhammad
.jpg/:/cr=t:25%25,l:0%25,w:100%25,h:50%25/rs=w:600,h:300,cg:true)
Natures V Autoimmune Disease Foundation Youtube channel video's link
Steps in Reducing the Affects of Myocarditis & Heart-related Diseases w/ Non-Medicinal Supplements
"Simple Steps in Reducing the Affects of Myocarditis and Other Heart-related Diseases via Non-Medicinal Supplements " w/ Mr. Victer Muhammad
https://www.youtube.com/live/3SlHfrp48og?si=Vtl_SMOoALJkqcqH
ifn case studies
West Nile
IFN-α/β acts as a key innate defense against WNV infection.
In vitro studies have demonstrated that pretreatment with IFN-α/β can reduce flavivirus replication in several cell populations, including Vero cells and human foreskin fibroblasts, although treatment after infection is generally less effective (1, 13, 14, 25, 34). Moreover, mouse embryonic fibroblasts that lack the IFN-α/β receptor show increased susceptibility to WNV infection (10). However, the potential role of endogenous IFN-α/β in modulating WNV infection in vivo was untested. Our experiments demonstrate that IFN-α/β is essential for controlling WNV infection. IFN-α/βR−/− mice had an MTD of 3.8 ± 0.5 days and 100% lethality following peripheral inoculation,
Monkey Pox
The purpose of this study was to investigate the prophylactic and therapeutic potential of interferon-β (IFN-β) for use against monkeypox virus. We found that treatment with human IFN-β results in a significant decrease in monkeypox virus production and spread in vitro. IFN-β substantially inhibited monkeypox virus when introduced 6-8 h post infection, revealing its potential for use as a therapeutic. IFN-β induced the expression of the antiviral protein MxA in infected cells, and constitutive expression of MxA was shown to inhibit monkeypox virus infection.
Covid 19 SARS-CoV and MERS-CoV.
Type 1 interferons as a potential treatment against COVID-19
Highlights
- •Interferon treatment has shown mixed efficiency against SARS-CoV and MERS-CoV.
- •SARS-CoV-2 is probably more sensitive to interferon than the other coronaviruses.
- •The IFNβ subtype appears to be the most suited for COVID-19 treatment.
- •Interferon treatment should be performed in the early stages of the infection.
- •Investigation on interferon-based COVID-19 treatment is warranted.
Myocarditis \ Heart Viruses
Interferon-β Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction
Kidney
Type I interferon (IFN-I) mediates tissue damage in a wide range of kidney disorders, directly affecting the biology and function of several renal cell types including podocytes, mesangial, endothelial, and parietal epithelial cells.
Treatment of Multiple Sclerosis
Interferons in the Treatment of Multiple Sclerosis
Interferon beta (IFNβ) was the first disease-modifying therapy available to treat multiple sclerosis (MS), providing patients with a treatment that resulted in reduced relapse rates and delays in the onset of disability.
Prostate
If customers can’t find it, it doesn’t exist. Clearly list and describe the services you offer. Also, be sure to showcase a premium service.
